UPPI LLC 2014 Molybdenum 99 (Mo 99) Topical Meeting


Washington, DC June 2014




UPPI Locations























- HEU to non-HEU derived Tc 99m with stepwise growth in the molecular imaging space
- Account for the CMS incentive for use of 95% LEU Tc 99m doses
- Market space conversion
- Hospital GPO conversion
 - Existing contracts
 - New Opportunities



- How to Address a Dual Inventory of Mo 99 Generators (HEU and LEU/non-HEU)?
 - Teeth-to-tail traceability of the LEU/non-HEU inventories until total conversion
 - Software enhancement to run dual inventory in the radiopharmacy
 - Generator Elution Kit QC Unit Dose
 - Internal cost accountability






What are we trying to achieve?


- Ability to accurately trace prescriptions to a LEU generator.
- Ability to charge appropriately for LEU prescriptions.







- Work with gradual LEU market penetration
- Build as supply becomes more robust
- Target to 100% conversion
 - Dual inventories unnecessary
 - Traceability
 - Measure success beyond HOPPS reimbursement
- Walk to next targeted market for conversion









- HEU shrinks as LEU/non-HEU expands
- What happens to HEU Mo 99 price when supply reaches a low volume?
- Is there a Full Cost Recovery tsunami?
- Does a domestic non-HEU source effect Full Cost Recovery efforts of current international suppliers?
- Where does the non-HEU Tc 99m per mCi price settle for the end user?

